SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-8.21 Insider Own0.20% Shs Outstand87.63M Perf Week4.09%
Market Cap10.51B Forward P/E- EPS next Y-4.72 Insider Trans149.27% Shs Float83.68M Perf Month17.09%
Income-716.20M PEG- EPS next Q-1.24 Inst Own89.10% Short Float / Ratio8.78% / 6.78 Perf Quarter13.14%
Sales876.00M P/S12.00 EPS this Y27.50% Inst Trans7.05% Short Interest7.35M Perf Half Y75.63%
Book/sh4.92 P/B24.99 EPS next Y40.60% ROA-23.20% Target Price140.26 Perf Year56.64%
Cash/sh24.24 P/C5.07 EPS next 5Y- ROE-97.40% 52W Range61.28 - 127.32 Perf YTD36.55%
Dividend- P/FCF- EPS past 5Y1.30% ROI-17.90% 52W High-4.89% Beta1.08
Dividend %- Quick Ratio4.00 Sales past 5Y164.50% Gross Margin83.90% 52W Low97.62% ATR4.82
Employees840 Current Ratio4.40 Sales Q/Q21.60% Oper. Margin-75.40% RSI (14)60.91 Volatility4.30% 3.85%
OptionableYes Debt/Eq3.58 EPS Q/Q-388.00% Profit Margin-81.80% Rel Volume0.39 Prev Close122.96
ShortableYes LT Debt/Eq3.58 EarningsNov 02 AMC Payout- Avg Volume1.08M Price121.10
Recom1.90 SMA207.43% SMA508.22% SMA20032.07% Volume145,919 Change-1.51%
Apr-04-22Resumed Cantor Fitzgerald Overweight $140
Jan-05-22Reiterated Needham Buy $157 → $150
Dec-09-21Upgrade Oppenheimer Perform → Outperform $125
Nov-05-21Upgrade JP Morgan Neutral → Overweight $130
Sep-15-21Upgrade Guggenheim Neutral → Buy
Aug-05-21Upgrade JP Morgan Underweight → Neutral $92 → $87
Jun-15-21Initiated BTIG Research Buy $110
Apr-26-21Resumed Credit Suisse Neutral $72
Jan-12-21Downgrade Citigroup Buy → Neutral $215 → $108
Jan-11-21Downgrade UBS Buy → Neutral
Show Previous Ratings
Dec-02-22 11:31AM
Nov-30-22 06:00PM
Nov-29-22 12:07PM
Nov-28-22 04:12PM
08:50AM
07:00AM Loading…
07:00AM
Nov-23-22 08:30AM
Nov-03-22 01:25PM
08:12AM
06:07AM
02:00AM
Nov-02-22 06:25PM
04:05PM
Oct-31-22 06:00PM
08:49AM
06:00AM Loading…
Oct-29-22 06:00AM
Oct-27-22 10:02AM
Oct-26-22 10:01AM
08:30AM
Oct-24-22 10:13AM
Oct-19-22 09:53AM
Oct-17-22 04:08PM
Oct-07-22 08:30AM
Oct-06-22 08:45AM
Sep-30-22 06:15PM
02:26PM
01:27PM
01:20PM
Sep-29-22 08:30AM
Sep-28-22 01:59PM
07:10AM Loading…
Sep-14-22 07:10AM
07:00AM
Sep-12-22 04:41PM
11:20AM
Sep-11-22 09:26AM
Sep-08-22 01:31PM
Sep-07-22 10:08AM
08:30AM
Sep-06-22 09:27AM
08:45AM
08:30AM
Sep-02-22 11:31AM
Sep-01-22 11:31AM
Aug-31-22 05:59PM
Aug-30-22 01:47PM
Aug-29-22 10:23AM
Aug-25-22 06:08AM
Aug-17-22 06:43PM
Aug-15-22 10:44AM
Aug-12-22 03:45PM
Aug-08-22 02:09PM
08:30AM
Aug-03-22 02:20PM
12:44PM
Aug-02-22 11:30PM
05:25PM
04:05PM
09:11AM
Aug-01-22 01:59PM
08:41AM
07:44AM
Jul-29-22 06:25PM
01:53PM
01:22PM
10:40AM
07:00AM
Jul-28-22 10:03AM
Jul-26-22 08:30AM
Jul-18-22 04:13PM
Jul-12-22 12:00PM
Jul-06-22 09:55AM
08:15AM
03:00AM
Jul-05-22 04:01PM
Jul-04-22 08:41AM
Jun-30-22 06:15PM
07:30AM
Jun-27-22 08:41AM
Jun-24-22 09:45AM
Jun-23-22 04:11PM
04:01PM
07:30AM
Jun-03-22 11:31AM
Jun-02-22 04:05PM
08:30AM
May-31-22 06:15PM
May-27-22 01:24PM
May-20-22 02:28PM
May-10-22 10:56AM
May-09-22 11:49AM
May-05-22 09:31AM
05:30AM
May-04-22 05:25PM
04:05PM
08:30AM
Apr-29-22 06:23PM
Apr-27-22 03:03PM
08:30AM
Apr-07-22 04:04PM
Mar-31-22 06:30PM
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mayo StephenDirectorNov 17Sale109.9285894,3116,387Nov 21 08:00 PM
Chambers Michael AndrewDirectorSep 14Buy104.4357,1005,963,124108,178Sep 15 08:00 AM
Chambers Michael AndrewDirectorAug 19Buy108.2846,1704,999,23051,078Aug 22 08:30 AM
BEHRENS M KATHLEENDirectorDec 15Option Exercise10.085,00050,400135,517Dec 16 08:00 PM
GRAY MARY ANNDirectorDec 10Option Exercise0.0096709,403Dec 14 08:02 PM